Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUENASDAQ:PBYINASDAQ:SELBNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$0.66+13.0%$0.71$0.45▼$1.99$49.39M1.41421,276 shs458,578 shsPBYIPuma Biotechnology$3.40-0.9%$3.22$2.23▼$4.13$168.74M1.29443,302 shs226,974 shsSELBSelecta Biosciences$1.06$0.81▼$1.99$136.76M0.84979,585 shs2.77 million shsZVRAZevra Therapeutics$9.07+3.0%$8.16$4.20▼$9.76$495.94M2.01669,856 shs432,294 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+3.11%-2.11%-33.42%-51.44%PBYIPuma Biotechnology0.00%-4.49%-6.34%-3.13%+10.03%SELBSelecta Biosciences0.00%0.00%0.00%0.00%0.00%ZVRAZevra Therapeutics0.00%-3.20%+5.34%+13.23%+103.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCUECue Biopharma4.0032 of 5 stars3.54.00.04.70.60.80.6PBYIPuma Biotechnology4.0839 of 5 stars3.52.00.00.01.84.23.1SELBSelecta BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AZVRAZevra Therapeutics2.7496 of 5 stars3.62.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 3.00Buy$3.00357.67% UpsidePBYIPuma Biotechnology 3.00Buy$7.00105.88% UpsideSELBSelecta Biosciences 0.00N/AN/AN/AZVRAZevra Therapeutics 3.11Buy$22.29145.71% UpsideCurrent Analyst Ratings BreakdownLatest PBYI, CUE, SELB, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$9.29M5.32N/AN/A$0.28 per share2.34PBYIPuma Biotechnology$230.50M0.73$0.85 per share3.99$1.88 per share1.81SELBSelecta Biosciences$110.78M0.00N/A9.91$0.61 per share0.00ZVRAZevra Therapeutics$23.61M21.01N/AN/A$0.74 per share12.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.774.428.95N/A16.37%49.35%18.25%7/30/2025 (Estimated)SELBSelecta Biosciences$35.38M-$0.22N/AN/AN/A-72.04%-44.13%-22.00%N/AZVRAZevra Therapeutics-$105.51M-$1.90N/A45.35N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest PBYI, CUE, SELB, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASELBSelecta BiosciencesN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A1.031.03PBYIPuma Biotechnology0.111.531.43SELBSelecta Biosciences0.214.184.18ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%PBYIPuma Biotechnology61.29%SELBSelecta Biosciences41.95%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma10.78%PBYIPuma Biotechnology23.30%SELBSelecta Biosciences31.20%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma6075.35 million67.23 millionOptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableSELBSelecta Biosciences64155.20 million106.78 millionOptionableZVRAZevra Therapeutics2054.68 million53.37 millionOptionablePBYI, CUE, SELB, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by AnalystsJune 20 at 2:07 AM | marketbeat.comCantor Fitzgerald Forecasts ZVRA FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Predicts ZVRA FY2026 EarningsJune 11, 2025 | marketbeat.comBank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 9, 2025 | marketbeat.comNuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 5, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLCJune 3, 2025 | marketbeat.comZevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 31, 2025 | finanznachrichten.deZevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth StrategyMay 31, 2025 | nasdaq.comZevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 29, 2025 | globenewswire.comCitizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PTMay 27, 2025 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by AnalystsMay 27, 2025 | marketbeat.comNorthern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 25, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street ZenMay 24, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LPMay 23, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest PositionMay 21, 2025 | marketbeat.comAll Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director NomineesMay 21, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystMay 20, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)May 16, 2025 | theglobeandmail.comWith 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interestMay 15, 2025 | finance.yahoo.comZevra Reports First Quarter 2025 Financial Results and Corporate UpdateMay 14, 2025 | taiwannews.com.twNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBYI, CUE, SELB, and ZVRA Company DescriptionsCue Biopharma NASDAQ:CUE$0.66 +0.08 (+13.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.69 +0.03 (+5.11%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Puma Biotechnology NASDAQ:PBYI$3.40 -0.03 (-0.87%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.45 +0.05 (+1.47%) As of 06/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Selecta Biosciences NASDAQ:SELBSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Zevra Therapeutics NASDAQ:ZVRA$9.07 +0.26 (+2.95%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.98 -0.10 (-1.05%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
